TSX Exchange Symbol: RVX
CALGARY, Nov. 15, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix" or the
"Company") (TSX:RVX) today announced that a patent covering RVX-208 has
been issued by the United States Patent and Trademark Office, adding to
the portfolio of patents held by Resverlogix.
Patent US 8,053,440 contains composition of matter claims to the
Company's clinical lead molecule, RVX-208, and structurally related
compounds. Other claims related to RVX-208 are being pursued in other
applications. In addition, Resverlogix has received notices of
allowance in other cases and are attending to formalities before these
patents issue. Corresponding applications in other jurisdictions are
"We are extremely pleased with the issuing of one of the key patents
covering RVX-208. It further solidifies Resverlogix as a key player in
the cardiovascular disease market and provides exclusive coverage for
RVX-208 until 2030," stated Donald McCaffrey, President & Chief
Executive Officer of Resverlogix.
Mr. McCaffrey continued, "Resverlogix devotes significant resources to
ensure the protection of ideas and inventions related to the core areas
of our business. Today, the Company's intellectual property portfolio
covers compositions, methods and treatments for cardiovascular and
inflammatory diseases, cancers and fibrotic diseases. We believe that
our know-how in these disease states will provide a significant
competitive advantage. Resverlogix intends to continue to develop and
protect our proprietary tools, methods, and trade secrets."
The Resverlogix patent portfolio currently consists of four issued
Compounds for the prevention and treatment of cardiovascular disease, US
Stilbenes and chalcones for the prevention and treatment of
cardiovascular diseases, US 7,846,915.
Pharmaceutical Compositions for the Prevention and Treatment of Complex
Diseases and Their Delivery by Insertable Medical Devices, NZ 566180.
Compounds and methods for down regulating the effects of TGF-beta, EP 1
648 520 B1.
It is the policy of Resverlogix to require employees, consultants,
members of our Scientific and Clinical Advisory Boards, and other third
parties in collaborative agreements to execute confidentiality
agreements. Employee, consultant and contract research organization
agreements specify that all inventions resulting from work performed
using the Company's resources and work completed during
employment/services performed are the Company's exclusive property, to
the extent permitted by law.
RVX-208 is a novel small molecule that stimulates endogenous ApoA-I
production to trigger the synthesis of HDL. The use of this approach
will enhance the functionality of HDL. ApoA-I is the major protein
component of HDL. The main role of these particles is to act as the
body's natural defense system against atherosclerosis by mediating a
normal physiologic process called reverse cholesterol transport (RCT).
This pathway enables cholesterol, including that within atherosclerotic
plaques of vessel walls, to be transported to the liver for further
processing and elimination from the body. Enhanced RCT clearance of
cholesterol from vessel walls should reduce or prevent atherosclerosis.
The ability of RVX-208 to increase ApoA-I production and thereby
augment RCT differentiates it from other HDL therapies. RVX-208 is
positioned to be one of the most promising drugs in development for the
treatment of atherosclerosis.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets
with significant unmet medical needs. The NexVas™ Plaque Regression
program is the Company's primary focus which is to develop novel small
molecules that enhance ApoA-I production. These vital therapies are
focused to address the burden of atherosclerosis and other important
diseases such as Acute Coronary Syndrome, Alzheimer's disease,
Peripheral Artery Disease and Autoimmune diseases. Resverlogix Corp.'s
common shares trade on the Toronto Stock Exchange (TSX:RVX). For
further information please visit www.resverlogix.com.
This news release may contain certain forward-looking information as
defined under applicable Canadian securities legislation, that are not
based on historical fact, including without limitation statements
containing the words "believes", "anticipates", "plans", "intends",
"will", "should", "expects", "continue", "estimate", "forecasts" and
other similar expressions. Our actual results, events or developments
could be materially different from those expressed or implied by these
forward-looking statements. We can give no assurance that any of the
events or expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous assumptions and risk
factors including but not limited to those associated with the success
of research and development programs, clinical trial programs including
possible delays in patient recruitment, the regulatory approval
process, competition, securing and maintaining corporate alliances,
market acceptance of the Company's products, the availability of
government and insurance reimbursements for the Company's products, the
strength of intellectual property, financing capability, the potential
dilutive effects of any financing, reliance on subcontractors and key
personnel and additional assumptions and risk factors discussed in our
Annual Information Form and most recent MD&A which are incorporated
herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of the
date hereof. The Company disclaims any intention and has no obligation
or responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE Resverlogix Corp.
For further information:
| Donald J. McCaffrey |
President & CEO
| Sarah Zapotichny |
Director, Investor Relations